Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 6, Pages e1438106
Publisher
Informa UK Limited
Online
2018-02-09
DOI
10.1080/2162402x.2018.1438106
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
- (2017) Richard D. Hall et al. Cancer Control
- Advances in immunotherapy for melanoma
- (2016) Jason M. Redman et al. BMC Medicine
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- TC-PTP and PTP1B: Regulating JAK–STAT signaling, controlling lymphoid malignancies
- (2016) Kelly A. Pike et al. CYTOKINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
- (2016) Katrina Meeth et al. Pigment Cell & Melanoma Research
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
- (2016) B. Homet Moreno et al. Cancer Immunology Research
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
- (2016) Giuseppe V. Masucci et al. Journal for ImmunoTherapy of Cancer
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
- (2015) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
- (2015) Mark Ayers et al. Journal for ImmunoTherapy of Cancer
- Acquired and intrinsic resistance in cancer immunotherapy
- (2014) Sander Kelderman et al. Molecular Oncology
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer
- (2013) J. M. Balko et al. CANCER RESEARCH
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- The role of BRAF V600 mutation in melanoma
- (2012) Paolo A Ascierto et al. Journal of Translational Medicine
- Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
- (2012) Justin M Balko et al. NATURE MEDICINE
- JAK/STAT signaling in hematological malignancies
- (2012) W Vainchenker et al. ONCOGENE
- MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC
- (2010) Justin M Balko et al. CANCER BIOLOGY & THERAPY
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases
- (2009) Xiaoyu Hu et al. IMMUNITY
- Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and Presentation
- (2009) Fang Zhou INTERNATIONAL REVIEWS OF IMMUNOLOGY
- IFNγ signaling—Does it mean JAK–STAT?
- (2008) Daniel J. Gough et al. CYTOKINE & GROWTH FACTOR REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search